Qiagen (NYSE:QGEN) Sets New 1-Year High at $47.17

Qiagen (NYSE:QGEN) shares reached a new 52-week high during trading on Wednesday . The stock traded as high as $47.17 and last traded at $47.08, with a volume of 270810 shares traded. The stock had previously closed at $46.97.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Wolfe Research upgraded shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price target for the company in a research note on Thursday, June 27th. JPMorgan Chase & Co. lifted their price objective on Qiagen from $52.00 to $54.00 and gave the company an “overweight” rating in a report on Tuesday, June 18th. Robert W. Baird increased their target price on Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. Finally, Stifel Nicolaus decreased their price target on Qiagen from $55.00 to $45.00 and set a “hold” rating on the stock in a research note on Wednesday, May 1st. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $51.10.

Qiagen Trading Down 0.9 %

The stock has a market cap of $10.56 billion, a price-to-earnings ratio of 31.34, a PEG ratio of 3.33 and a beta of 0.40. The business has a fifty day simple moving average of $43.24 and a 200 day simple moving average of $43.17. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.46 and a current ratio of 1.77.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, July 31st. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.52 by $0.03. The company had revenue of $496.00 million for the quarter, compared to analyst estimates of $495.45 million. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. The firm’s quarterly revenue was down .2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.53 EPS. As a group, equities analysts anticipate that Qiagen will post 2.15 EPS for the current year.

Institutional Trading of Qiagen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in QGEN. Cerity Partners LLC purchased a new stake in Qiagen in the fourth quarter valued at approximately $220,000. Xponance Inc. grew its stake in shares of Qiagen by 2.7% during the 4th quarter. Xponance Inc. now owns 9,609 shares of the company’s stock valued at $417,000 after buying an additional 253 shares during the period. Lindbrook Capital LLC increased its holdings in shares of Qiagen by 21.6% during the 4th quarter. Lindbrook Capital LLC now owns 1,335 shares of the company’s stock worth $58,000 after buying an additional 237 shares during the last quarter. Signaturefd LLC raised its position in shares of Qiagen by 54.4% in the 4th quarter. Signaturefd LLC now owns 7,236 shares of the company’s stock worth $314,000 after buying an additional 2,550 shares during the period. Finally, Sector Gamma AS boosted its holdings in Qiagen by 89.2% in the fourth quarter. Sector Gamma AS now owns 190,539 shares of the company’s stock valued at $8,275,000 after acquiring an additional 89,826 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.